PYXS PYXS
Company Profile ↓Company Overview
PYXS (PYXS) is a publicly traded company listed on with a market capitalization of $196.22M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.35.
Recent Developments
- Dec 2025 Revenue of $13.86M (-14.2% YoY); net profit $-79.62M.
- Trailing 12 Months Year-on-year growth — revenue -14.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -14.17% |
Stock Price Performance
| 1 Year: | +184.55% |
| 6 Months: | +110.07% |
| 3 Months: | +71.04% |
| 1 Month: | +1.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 41.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 16.15M | - | - | - | 0 | 2.82M | 0 | 11.04M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 2.39M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 2.82M | 0 | 8.65M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.91M | 22.57M | 23.46M | 26.95M | 24.36M |
| Operating Income | - | - | -3.19M | -35.73M | -5.94M | -11.62M | -31.39M | -25.73M | -28.39M | -20.95M | -18.12M | -25.35M | -5.61M | -20.03M | -23.75M | - | -22.91M | -19.75M | -23.46M | -18.30M | -24.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.36M | -19.21M | -22.93M | -15.40M | -23.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -21.16M | -18.07M | -22.00M | -17.00M | -23.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 283.00K | 0 | 1.10M | - |
| Net Income | -1.96M | -3.10M | -3.19M | -36.83M | -8.15M | -14.18M | -31.38M | -25.56M | -27.67M | -19.24M | -15.90M | -23.05M | -3.26M | -17.30M | -21.20M | - | -21.16M | -18.35M | -22.00M | -18.11M | -23.27M |
| Diluted EPS | - | - | - | - | -5.54 | -8.96 | -0.97 | -0.79 | -0.85 | -0.54 | -0.41 | -0.56 | -0.06 | -0.29 | -0.35 | - | -0.35 | -0.30 | -0.35 | - | -0.37 |
| R&D Expense | - | - | 2.42M | 32.77M | 3.21M | 7.85M | 20.07M | 17.17M | 19.03M | 11.90M | 11.39M | 14.69M | 13.03M | 13.95M | 17.74M | - | 17.04M | 17.13M | 17.81M | - | 19.98M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 16.15M | 13.86M |
| Cost of Revenue | - | - | - | 0 | 475.00K | 2.39M |
| Gross Profit | - | - | - | 0 | 15.67M | 11.47M |
| Operating Expenses | - | - | 123.48M | 82.20M | 84.17M | 95.89M |
| Operating Income | -12.89M | - | -123.48M | -82.20M | -68.50M | -84.42M |
| EBITDA | - | - | -122.77M | -80.27M | -65.51M | -79.91M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -120.72M | -73.79M | -79.50M | -78.23M |
| Tax Provision | - | - | - | 0 | -2.16M | 1.39M |
| Net Income | -12.83M | - | -120.72M | -73.79M | -77.33M | -79.62M |
| Diluted EPS | - | - | -3.65 | -1.85 | -1.32 | -1.28 |
| R&D Expense | 9.05M | 51.05M | 86.13M | 49.59M | 58.75M | 73.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.15M | - | 211.38M | 173.73M | 157.18M | 91.52M |
| Current Assets | - | - | - | 186.61M | 124.60M | 132.44M | 72.11M |
| Cash & Equivalents | - | 8.08M | - | 179.29M | 9.66M | 19.47M | 15.42M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 598.00K | 21.00K | 0 | 700.00K |
| Total Liabilities | - | 3.85M | - | 50.55M | 48.02M | 36.43M | 38.11M |
| Current Liabilities | - | 3.69M | - | 31.63M | 25.76M | 17.68M | 21.13M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 18.92M | 21.33M | 20.20M | 18.67M |
| Total Equity | -2.87M | -15.64M | - | 160.82M | 125.70M | 120.75M | 53.41M |
| Shares Outstanding | - | - | - | 34.96M | 44.75M | 59.97M | 62.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.08M | - | -89.33M | -70.71M | -57.67M | -63.50M |
| Investing Cash Flow | -1.48M | - | -6.40M | -104.85M | 8.15M | 58.86M |
| Financing Cash Flow | 35.00K | - | 183.00K | 5.93M | 59.33M | 594.00K |
| Capital Expenditure | -1.48M | - | -6.40M | -6.73M | -237.00K | -9.00K |
| Free Cash Flow | -11.57M | - | -95.73M | -77.44M | -57.91M | -63.51M |
| Net Change in Cash | - | - | -95.55M | -169.63M | 9.81M | -4.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 97.1% | 82.8% |
| Operating Margin % | - | - | - | - | -424.2% | -609.2% |
| Net Margin % | - | - | - | - | -478.9% | -574.5% |
| ROE % | 82.0% | - | -75.1% | -58.7% | -64.0% | -149.1% |
| ROCE % | -199.5% | - | -68.7% | -55.6% | -49.1% | -119.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PYXS
Pyxis Oncology Secures Up to $114 Million Private Placement
Pyxis Oncology (PYXS) said Tuesday it entered into definitive agreements for a private placement exp
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase 1 monotherapy data in Fall 2026 and updat…
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS)
While Pyxis Oncology, Inc. (NASDAQ:PYXS) has gained 54.78% year-to-date, analysts continue to see 293.30% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. That analyst conviction is rooted in a busy clinic…
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a do…
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following…
Creative Global Technology Holdings And 2 Other Promising Penny Stocks
Over the last 7 days, the U.S. market has risen by 2.6%, and in the past year, it has climbed an impressive 26%, with earnings forecasted to grow by 17% annually. In such a robust market environment, identifying stocks with solid financials…
PYXS — Frequently Asked Questions
What is the current share price of PYXS?
As of 2026-08-05 17:25 PDT, PYXS trades at $3.13 on NASDAQ/NYSE. Its 52-week range is $1.04 to $5.34.
What is the market capitalisation of PYXS?
PYXS has a market capitalisation of $196.22M on NASDAQ/NYSE.
What is the P/E ratio of PYXS?
PYXS trades at a trailing price-to-earnings (P/E) ratio of -2.45. Its price-to-book (P/B) ratio is 3.67.
What is the return on equity (ROE) of PYXS?
PYXS has a return on equity (ROE) of -149.08%. Its return on capital employed (ROCE) is -119.93%.
Is PYXS a good stock to buy?
This page provides a data-driven analysis of PYXS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.